Evenity vs Tymlos
A side-by-side look at two bone health medications advertised on TV. Informational only — not medical advice.
| US Evenity | US Tymlos | |
|---|---|---|
| Generic name | romosozumab | abaloparatide |
| Drug class | Sclerostin Inhibitor (Biologic) | PTHrP Analog (Bone-Building Agent) |
| Treats | Osteoporosis (high fracture risk) | Osteoporosis |
| Category | Bone Health | Bone Health |
| Manufacturer | Amgen/UCB | Radius Health |
| Year approved | 2019 | 2017 |
| FDA warning | Black box warning | Black box warning |
| Est. TV ad spend | $70M | — |
| Common side effects | Heart attack or stroke risk, Joint pain, Headache, Low blood calcium | Dizziness, Nausea, Headache, Heart palpitations |
Frequently asked questions
Is Evenity or Tymlos better?
Neither is universally "better." Evenity (romosozumab) and Tymlos (abaloparatide) are both used for bone health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Evenity and Tymlos?
Evenity is a Sclerostin Inhibitor (Biologic) made by Amgen/UCB, while Tymlos is a PTHrP Analog (Bone-Building Agent) made by Radius Health. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Evenity has the larger estimated TV advertising budget of the two.